Table 3.

Mean part-worth utility values (rescaled as zero centred) for the n=1004 respondents

Attributes and levels	Mean part-worth utility	SE	t Values	Mean significantly different from 0
MD's clinical risk estimate
Low risk	−29.81	2.55	−11.68	***
Intermediate risk	0.20	0.89	0.22	NS
High risk	29.61	2.48	11.95	***
Trust in MD
Do not trust	−25.54	0.98	−26.10	***
Somewhat trust	−0.73	0.67	−1.09	NS
Totally trust	26.27	0.92	28.55	***
Likelihood of temporary SE
Low likelihood	2.47	0.75	3.27	**
Moderate likelihood	7.55	0.60	12.60	***
High likelihood	−10.02	0.75	−13.34	***
Likelihood of permanent SE
Low likelihood	33.75	1.10	30.59	***
Moderate likelihood	12.25	0.76	16.13	***
High likelihood	−46.00	1.22	−37.66	***
GEP score, likely benefit from chemotherapy
GEP not available	−17.34	0.86	−20.18	***
9, Low benefit	−43.39	1.21	−35.73	***
22, Uncertain benefit	−6.83	0.89	−7.65	***
44, High benefit	67.56	1.52	44.48	***
General preference for chemotherapy vs no chemotherapy	−49.53	5.74	−8.63	***

Conducting paired t-test among attribute levels within each attribute, all pairs were significantly different at p<0.001.

**Significant at p<0.01; ***Significant at p<0.001.

GEP, gene expression profiling; MD, cancer treatment doctor; NS, not significant; SE, side effects.